Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase IIa Study of ALLOB allogeneic osteoblastic cells in lumbar spinal fusion
2013-004480-31Phase 2Completed
- Sponsor
- BioSenic
- Start
- Mar 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic osteoblastic cells in Degenerative disc disease of the lumbar spine and pseudoarthrosis, sponsored by BioSenic. Primary endpoints: Safety over 12 months and Efficacy of spinal fusion. Started Mar 2014; status: completed.
02
Drugs
allogeneic osteoblastic cells
03
Conditions
Degenerative disc disease of the lumbar spinepseudoarthrosis
Beyond the preview
Go deeper on 2013-004480-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004480-31.